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ِرّي الباِدِئ ِعنَْد النُّْضج احملدد سريريا عند البالغني  كَّ داء السُّ
الُعمانيني صغار السن
غياب املوّرثات اجلينية الشائعة يف الغرب
نيكوالس وودهاوس، أميمة الشفيع، علي املعمري، ناجي هاشم، فاطمة  الريامي، ساندي رايبرن
ال�شكري  مر�س  ال�رسيرية  خ�شائ�شه  ت�شابه  الذي  ال�شكر  بداء  امل�شابني  ال�شن  �شغار  املر�شى  من  متزايدة   اأعدادا  ن�شنقبل  الهدف:  امللخ�ص: 
الباديء عند الن�شج حيث التاريخ االأ�رسي ي�شري اىل تاأثر م�ّرث اأحادي، مع غياب الدليل الذي ي�شري اىل وج�د داء ال�شكري من الن�ع االأول ذي 
 ،1α - 4 ، والعامل الكبدي الن�ويα املناعة الذاتية.  الهدف من هذه الدرا�شة حتديد م�ش�ؤولية الطفرات ال�راثية الثالثة )العامل الكبدي الن�وي
واجلل�ك�كاينيز( االكرث �شي�عا بني املر�شى الغربيني من عدمه عند البالغني الُعمانيني �شغار ال�شن. الطريقة: متت الدرا�شة يف م�شت�شفى جامعة 
ال�شلطان قاب��س ب�شلطنة ُعمان، حيث مت اختيار ع�رسين مري�شا بالغا من �شغار ال�شن ممن لهم تاريخ اأ�رَسي باحتمالية الت�ريث مب�ّرث واحد 
بفرتة تقل عن )18( �شهرا، وكان مت��شط االأعمار )25( �شنة مع و�شيط من�شب كتلة اجل�شم )29(. اأجري التحري ل�ج�د م�شادات املناعة الذاتية 
�شد خاليا  البنكريا�س اجلزيرية – ن�ع ب- و ناِزَعُ الَكْرُب�ك�ِشيل حلام�س اجلل�تاميك وكان �شلبيا. وافق اأربعة ع�رس مري�شا على اإجراء حتري 
َ�ِوي  َمْنُزوع االأوك�ِشجني للطفرات اجلينية يف االك�ش�ن )10-1( من انزمي ناِزَعُ الَكْرُب�ك�ِشيل حلام�س اجلل�تاميك  واالك�ش�ن )10-2( من م�ّرثات فح�س الدم ال�راثي ومت اإر�شاله ل�حدة الربوفي�ش�ر هاتر�شلي يف كلية الطب بباك�شرت )اململكة املتحدة(، حيث مت فح�س احَلْم�ُس الرِّْيِبيُّ النَّ
(، الطفرات ال�راثية االأكرث �شي�عا يف اوروبا.  النتائج: مل يتم العث�ر على اأي من   4α (  1 (  والعامل الكبدي الن�ويα (العامل الكبدي الن�وي
الطفرات ال�راثية املذك�رة يف اأي من املر�شى. اخلال�صة: يف هذه املجم�عه ال�شغرية من املر�شى العمانيني البالغني �شغريي ال�شن الذين تطابق 
ج  مل يتم العث�ر على اأي من الطفرات ال�راثية الثالث االأكرث �شي�عا يف الغرب. وهذا قد يك�ن ناجتا  حالتهم ال�رسيرية داء ال�شكري الباِدُئ ِعْنَد النُّ�شْ
من وج�د طفرات جديدة يف املر�شى العمانيني اأو اأن ه�ؤالء املر�شى يعان�ن من داء ال�شكري من الن�ع الثاين نتيجة لت�ريث بع�س امل�ّرثات 
التي ت�شكل خطرا يف اال�شابة املبكرة بداء ال�شكري من الن�ع الثاين الذي يتميز ب�ج�د مقاومة كبرية لالن�ش�لني ناجتة عن ال�شمنة . 
ج، طفرات، داء ال�شكري العائلي، البالغني ال�شغار، ُعمان. ِريُّ الباِدُئ ِعْنَد النُّ�شْ كَّ  مفتاح الكلمات: داء ال�شكري – الن�ع الثاين، داء ال�شُّ
abstract: Objectives: We are seeing a progressive increase in the number of young patients with clinically 
defined maturity onset diabetes of the young (MODY) having a family history suggestive of a monogenic cause 
of their disease and no evidence of autoimmune type 1 diabetes mellitus (T1DM). The aim of this study was to 
determine whether or not mutations in the 3 commonest forms of MODY, hepatic nuclear factor 4α (HNF4α), 
HNF1α and glucokinase (GK), are a cause of diabetes in young Omanis. Methods: The study was performed at 
Sultan Qaboos University Hospital (SQUH), Oman. Twenty young diabetics with a family history suggestive of 
monogenic inheritance were identified in less than 18 months; the median age of onset of diabetes was 25 years and 
the median body mass index (BMI) 29 at presentation. Screening for the presence of autoimmune antibodies against 
pancreatic beta cells islet cell antibody (ICA) and glutamic acid decarboxylase (GAD) was negative.  Fourteen of 
them consented to genetic screening and their blood was sent to Prof. A. Hattersley’s Unit at the Peninsular Medical 
School, Exeter, UK.  There, their DNA was screened for known mutations by sequencing exon 1-10 of the GCK and 
exon 2-10 of the HNF1α and HNF4α genes, the three commonest forms of MODY in Europe. Results: Surprisingly, 
none of the patients had any of the tested MODY mutations. Conclusion: In this small sample of patients with 
clinically defined MODY, mutations of the three most commonly affected genes occurring in Caucasians were not 
observed.  Either these patients have novel MODY mutations or have inherited a high proportion of the type 2 
diabetes mellitus (T2DM) susceptibility genes compounded by excessive insulin resistance due to obesity.
Keywords: Diabetes Mellitus, Type II; Diabetes mellitus, maturity onset; MODY; mutations; Diabetes, familial; 
Young adults; Oman. 
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Diabetes mellitus (DM), both types I and II, is common worldwide and now affects more than 5% of all obese 
adolescents;1-4 however, optimal investigation and 
management is still unclear. Doctors often struggle 
to provide the best therapy, especially in regions 
where lifestyle changes in the last one or two 
generations have contributed to the diabetogenic 
risk.
In Oman, as in other countries of the Arabian 
Peninsula, type 2 diabetes (T2DM) especially 
and other complex, multifactorial disorders have 
reached epidemic levels.5 We are now seeing a 
progressive increase in the number of young Omani 
diabetics (<25 years) with a family history indicating 
a monogenic cause of their disease and who have no 
evidence of type 1 diabetes mellitus (T1DM). These 
patients have clinically defined maturity onset 
diabetes of the young (MODY), a disorder resulting 
from mutation in 6 different genes causing deficient 
insulin secretion. They are often misdiagnosed as 
T1DM and treated with insulin.  However, some 
patients have mutations in the genes encoding 
HNF1α or β-cell potassium adenosine triphosphate 
(K-ATP) channels both of which respond well to 
low dose sylphonylurea (SU) therapy. To date, we 
have identified three such families (not included 
in the present study) who were able to discontinue 
insulin and continue on SU therapy alone. Clearly 
therefore, MODY exists in Oman and in this study 
we have screened an additional 14 patients for 
common MODY mutations.  
Methods
Twenty young diabetics with a family history 
suggesting monogenic inheritance [Figure 1], 
and whose antibodies against pancreatic beta-
cells islet cell antibodies (ICA) and glutamic acid 
decarboxylase (GAD)) were negative, were identified 
in less than 18 months. Of these 14 patients, whose 
characteristics are shown in Table 1, consented to 
genetic screening and their blood was sent to the 
Molecular Genetics Laboratory at the Peninsular 
Medical School, Exeter, UK. There, their DNA 
was screened for known mutations by sequencing 
exon 1-10 of the glucokinase gene and exon 2-10 
of the HNF1α and HNF4α, the commonest forms 
of MODY in Europe6 using the DNA ABI PRISM® 
3100 Genetic Analyzer,
Results and Discussion
In this small group of young Omani diabetics, 
we expected to find several with known MODY 
mutations, particularly as we have already 
identified 3 different MODY families responsive 
to SU therapy. Surprisingly, this was not the case 
and mutations in the three commonest forms 
of MODY were not observed, although all had 
family histories suggestive of a monogenic cause 
of their disease and no evidence of T1DM.  How 
might this be explained?  Either these patients had 
novel MODY mutations or have inherited one or 
more of the T2DM susceptibility genes. Novel 
mutations cannot be ruled out as, in a recent and 
larger Danish study, mutations were found in only 
half the patients with clinically defined MODY, as 
ours.7 Interestingly, patients with clinically defined 
MODY in Mexico and China8,9 have few of the 
documented mutations occurring in Caucasians 
which suggests that our Omani MODY patients 
may have novel gene mutations as well. However, 
we suspect that early onset T2DM is more likely, 
particularly as the median BMI in our study group 
was 29, an additional factor associated with early 
onset disease.
MODY is a familial monogenic form of diabetes 
with autosomal dominant inheritance and high 
penetrance of 80–95%. In contrast to type 1 and 
type 2 diabetes, MODY usually develops below 25 
years6,10 [Figure 2]. Currently there are 6 identified 
gene mutations, three of them, HNF1α, HNF4α 
and glucokinase, are common and account for 
>80% of MODY cases in Europe and North 
America, while others are rare (HNF1β, insulin 
promoter factor 1 and neurogenic differentiation 
factor 1).10 Some of the MODY patients will not 
Advances in Knowledge 
1. It would appear that the maturity onset diabetes of the young mutations common in Caucasians are rare in Oman.
Application to Patient Care
1. Families with mutations of the beta cells potassium ATP channels may be identified and thus the use of insulin avoided
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have a known gene mutation (MODY X), but 
efforts are on going to determine the responsible 
mutations.10, 11  
With young patients, the clinician should 
distinguish between T1DM (with autoimmune 
destructions of the beta-cells and insulin 
dependence), monogenic defects due to the 
maturity onset of diabetes in the young (MODY) 
and T2DM which is multifactorial.3,12,13 With 
their early age of onset, patients with single gene 
disorders such as MODY are often misdiagnosed 
as T1DM and inappropriately treated with 
insulin.12,14-16 This is unfortunate as patients 
with glucokinase deficiency (GKD) have few 
complications and rarely require treatment.13,17 
Furthermore, patients with transcriptions factor 
mutations (such as HNF1α and neonatal Kir6.2) 
respond dramatically to sulphonylurea medication.14 
Recently, we have successfully switched diabetics, 
from three families, from insulin of many years 
duration to oral SUs. Although monogenic DM in 
the UK is only estimated to occur in 1–2% of the 
diabetic population (i.e. up to 40,000 patients), 
in Oman the incidence of monogenic disease is 
probably much higher due to the higher rate of 
consanguinity.
Mutagenesis screening is expensive so we are 
now actively screening candidate patients using 
a trial of SU therapy. Screening is carried out in 
patients aged <30 years who are taking insulin, 
have a positive family history and no GAD or ICA 
antibodies. Of the 10 patients studied so far 3 have 
gratifyingly responded to low dose SU therapy. This 
trial is currently in progress, together with screening 
of the patients for the T2DM susceptibility genes 
which are currently known to be associated with 
T2DM.18-21
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Figure 1: Pedigree of index Omani patient. The 
numbers indicate the age at diagnosis






Legend: MODY = maturity onset diabetes of the young 
Figure 2: Age at onset with differnt types of diabetes
Table 1: Details of the 14 patients with a family history suggesting a monogenic cause of their disease. Shown is 
the median and range of age and BMI at diagnosis. Four were taking insulin alone and 10 oral hypoglycaemic 
agents.
Age at diagnosis/Yr 
Median
Sex BMI Therapy GAD / ICA
20 (12-40) 10 M 29 INS Negative
4 F 20-41 OHA Negative
Legend: BMI = body mass index; GAD = glutamic acid decarboxylase; ICA =islet cell antibody; INS = insulin; OHA = oral hypoglycaemic agents
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